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Abstract
Purpose Pulmonary vein isolation (PVI) by catheter ablation has reduced efficacy for the treatment of persistent atrial fibrillation
(persAF), as compared to paroxysmal atrial fibrillation (paroxAF). We investigated whether the selection of persAF patients for
PVI who Bstep back^ to the paroxysmal stage on amiodarone offers a success rate comparable to that of patients with paroxAF.
Methods Sixty-two consecutive persAF patients and 62 matched control patients with paroxAF were included.
Persistent patients were started on amiodarone and cardioverted to sinus rhythm (SR). PVI was performed after
3 months in those who Bstepped back^ and had sustained SR and in all paroxAF patients.
Results Five of the 62 (8%) study patients returned to persAF after cardioversion; despite amiodarone, they did not
undergo PVI. The rest received PVI and was followed for a mean of 31 ± 14 months. Redo procedures were performed
in 44% and 29% in the persAF and paroxAF group (p = 0.093), respectively. The recurrence rate after multiple
procedures without antiarrhythmic drugs was similar among the persAF and paroxAF patients (11% and 7%) at
6 months (p = 0.510), but increased in the persAF group at 1 year (21% and 9%, p = 0.065) and exceeded that of
the paroxAF group at the end of the follow-up (26% and 12%, p = 0.046). Kaplan-Meier survival analysis showed
shorter time to recurrence in the persAF group (p = 0.045).
Conclusion PersAF patients who Bstep back^ to the paroxysmal stage on amiodarone can expect long-term success of a
PVI-only strategy in more than 70% of the time. However, late recurrences are more common compared to paroxAF.
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1 Introduction
Pulmonary vein isolation (PVI) by catheter ablation has
reduced efficacy for the treatment of persistent atrial fibril-
lation (persAF), as compared to paroxysmal atrial fibrilla-
tion (paroxAF) [1]. In the mechanism of the latter, triggers
from the pulmonary veins (PVs) have a dominant role [2].
However, there is a considerable progression of atrial fi-
brillation (AF) over time, characterized by remodeling of
the atria and persistence of AF by extrapulmonary sources
[3, 4]. Several techniques have been developed to address
extrapulmonary sources, including left atrial (LA) linear
ablation and electrogram-based ablation; however, these
have not consistently improved outcomes when added to
PVI [1, 5]. Previous studies have suggested that a better
outcome of PVI may be expected in those persAF patients
who can be maintained in sinus rhythm (SR) by aggressive
antiarrhythmic drug (AAD) pretreatment, compared with
those who return to persAF despite such efforts [6, 7].
Therefore, another approach to improve ablation success
in persAF would be the selection of patients for PVI,
whose atrial remodeling is reversible and is able to Bstep
back^ to the paroxysmal stage on AAD. Amiodarone has
superior efficacy in AF and has been shown to be able to
reverse atrial remodeling in an animal model [8, 9].
Therefore, we tested the hypothesis that when pretreatment
of persAF patients by amiodarone results in a Bstep back^
to the paroxysmal stage, the efficacy of PVI would be
comparable to that of patients with true paroxAF.
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2 Methods
2.1 Patients
The study group consisted of consecutive patients with symp-
tomatic, persistent atrial fibrillation (persAF) resistant to AAD
therapy, other than amiodarone. No study patient has been on
amiodarone previously. PersAF was defined as an arrhythmia
lastingmore than 1 week according to the European Society of
Cardiology [10]. Patients with prior LA ablation, reduced left
ventricular ejection fraction, and valvular heart disease and
aversion or a contraindication for amiodarone were excluded.
No patient with documented persAF lasting more than 1 year
was included.
For the control group, we selected consecutive patients
with symptomatic paroxAF, from a contemporaneous popula-
tion undergoing their first pulmonary vein isolation (PVI),
after the failure of rhythm control with propafenone or sotalol.
Controls were matched with the study group in age, gender,
comorbidities, and echocardiographic LA dimension to en-
sure the same distribution of these characteristics in the two
groups. There was no patient previously on amiodarone in the
control group.
2.2 Periprocedural antiarrhythmic drug protocol
Amiodarone was initiated for the patients with persAF after
transoesophageal echocardiography (TOE) ruled out intracar-
diac thrombi. The drug was administered in a dose of 800 mg/
day during the first week, 400 mg/day during the second
week, and 200 mg afterwards. After at least 1 month of ami-
odarone treatment, patients underwent electrical cardiover-
sion, if still in persAF. Patients without recurrence of persAF
during the ensuing 2 months underwent PVI. Amiodarone
was continued for the 8-week blanking period after PVI and
stopped thereafter. In the control group, any AAD therapy was
discontinued before the procedure and reinitiated only if re-
currences occurred. Therefore, no patient without recurrences
continued to receive AADs beyond the blanking period.
2.3 Pulmonary vein isolation
After providing written informed consent according to insti-
tutional protocols, all patients underwent antral pulmonary
vein isolation in sinus rhythm (SR), without any additional
linear ablation, except a right atrial flutter line in patients with
documented or induced typical atrial flutter. Radiofrequency
energy was applied with a deflectable irrigated catheter, using
a point-by-point technique. The procedures were guided by a
real-time 3D non-fluoroscopic navigation system (NavX or
CARTO) and intracardiac echocardiography. A circular map-
ping catheter was used for the recording of PV potentials and
the verification of the isolation. Complete isolation of all the
PVs after a 30-min waiting period was the endpoint of the
procedure.
2.4 Patient follow-up
Patients had follow-up visits 3 months, 6 months, and 1 year
after the procedure, and yearly thereafter. Symptom status, 12-
lead ECG, 24-h or 1-week Holter ECG, and transtelephonic
ECGwere used for assessing AF recurrence. All patients with-
out symptoms underwent 1-week Holter monitoring 15 ±
2 months (median 15 months) after the last procedure to test
for asymptomatic recurrences. Recurrences were defined as
any atrial arrhythmia lasting more than 30 s. Success was
defined as no recurrences beyond the blanking period off all
AADs. Patients who had their AADs reinitiated because of
recurrences were considered to have failed PVI. In case of
documented AF recurrence, a redo procedure was recom-
mended for symptomatic patients. During redo PVI, all
reconnected PVs were reisolated, and it was followed by the
same outpatient care protocol as the index procedure. In case
of redo ablation, the follow-up time was calculated after the
last procedure. Patients who had not completed the 6-month
follow-up after the redo PVI were excluded from the multiple-
procedure analysis and were considered failures in the single-
procedure analysis.
2.5 Statistical analysis
IBM SPSS Statistics 23 was used for statistical analysis.
Continuous variables are indicated as mean ± SD, and cate-
gorical variables are expressed in percentage form. The differ-
ence between the study and the control group was tested with
Student’s t test in case of continuous variables and the chi-
square test was used for the categorical variables. We used the
Cox regression to estimate hazard ratios (HR) and 95% con-
fidence intervals (CI) for arrhythmia recurrence in the two
groups at 6 months, 1 year, and at the end of the follow-up.
The time to recurrence during the follow-up period was tested
by the Kaplan-Meier curve with the log-rank analysis.
Logistic regression was utilized to determine the predictor
factors of AF recurrence. p < 0.05 was considered statistically
significant.
3 Results
3.1 Patient characteristics
Sixty-two consecutive patients were included in the study
group. They all had ongoing persAF at the time of inclusion
(mean duration, 3.8 ± 3.9 months; median, 2 months). Twenty
of them (32%) had previously undergone cardioversion for
persAF; for the rest, the qualifying persistent episode was
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the first one. None of them was experiencing concurrent
paroxAF episodes. All of the included patients had successful
cardioversion after amiodarone loading; however, 5 patients
(8%) returned to persAF during the subsequent 2 months and
did not undergo ablation. The remaining 57 patients Bstepped
back^ from persAF to having only paroxysmal episodes or
sustained SR with amiodarone treatment and underwent PVI
as per protocol.
There was no difference between the study patients and the
control group (N = 62) in demographic data, comorbidities,
and echocardiographic parameters. Left ventricular ejection
fraction, antero-posterior left atrial diameter, grade of sponta-
neous left atrial echo contrast, and the flow velocity of the left
atrial appendage on TOE were investigated. All persAF pa-
tients were studied during ongoing arrhythmia (before cardio-
version), while paroxAF patients were generally studied in SR
(Table 1).
The mean follow-up time was 30.2 ± 13.6 vs. 29.8 ±
14.4 months after the first procedure and 23.13 ± 13.4 vs.
24.9 ± 13.9 months after the last procedure, in the study and
control groups, respectively (p =NS). Two patients were lost
after 6 months to follow-up; otherwise, all patients completed
at least 1-year follow-up.
The rate of redo procedures tended to be higher in the study
group (44% vs. 29%, p = 0.093).
3.2 Efficacy of pulmonary vein isolation
Isolation of all four pulmonary veins (PVI) was achieved in all
patients at the index procedure in both groups. After the first
procedure, 56% of patients achieved complete arrhythmia
freedom without AAD. In the control group, the single proce-
dure success was significantly better compared with the per-
sistent group (64.5% vs. 44%, p = 0.028). In five patients
(4%), rhythm control strategy was abandoned after the first
procedure due to the lack of symptoms, patients’ preferences,
or severe comorbidities. Redo procedures were performed in
44% (n = 25) of persAF and 29% (n = 18) of paroxAF patients
(p = 0.093), respectively. PV reconnection was observed in
95.8% in persAF and 93.3% in paroxAF patients. The number
of reconnected PVs was comparable in the two groups (2.2 ±
1.1 vs. 1.9 ± 1, p = 0.463). A second redo PVI was done in
three cases, all of which showed extensive PV reconnections
during the first redo PVI. The total number of ablation proce-
dures was 84 in persAF group and 81 in paroxAF group. After
the last procedure, at 6-month follow-up, there was no statis-
tically significant difference in the recurrence rate between the
two groups (11% vs. 7%, p = 0.510; HR, 1.87; 95%CI, 0.528–
6.639). The difference started to emerge at the 12-month fol-
low-up (21% vs. 9%, p = 0.065; HR, 2.648; 95%CI, 0.905–
7.750) and became significant by the end of the follow-up
(26% vs. 12%, p = 0.046; HR, 2.52; 95%CI, 1.003–6.324).
The Kaplan-Meier survival curves after the first and multiple
procedures are shown in Figs. 1 and 2. ParoxAF patients
showed significantly longer mean time to recurrence com-
pared with persAF patients (26.6 ± 1.8 vs. 22.7 ± 1.7 months
after the first procedure and 33.2 ± 1.2 vs. 29.4 ± 1.8 months
after the last procedure, respectively, p = 0.045).
In a multivariable analysis including demographic data,
comorbidities, and echocardiographic parameters, only age
emerged as a significant predictor for the failure of PVI
(Table 2).
4 Discussion
Pulmonary vein (PV) isolation (PVI) is currently the only
validated approach for the non-pharmacologic treatment of
persistent atrial fibrillation (persAF). However, the success
of PVI in persAF remains limited when compared with par-
oxysmal atrial fibrillation (paroxAF). The lower success rate
in persAF is likely due to adverse remodeling of the atria and
emergence of non-PV sources of AF. There is evidence how-
ever that atrial remodeling can be reversed when sinus rhythm
(SR) is restored for prolonged periods [11]. Previous studies
have suggested a better outcome of PVI in persAF patients,
Table 1 Baseline clinical
characteristics and
echocardiographic parameters
Persistent AF (N = 57) Paroxysmal AF (N = 62) p value
Male gender (%) 68.4 69.4 0.611
Hypertension (%) 89.5 80.6 0.208
Age (years) 62.7 ± 8.6 61.21 ± 7.7 0.315
Diabetes mellitus (%) 19 16.1 0.683
Coronary disease (%) 5.2 6.5 0.765
Ejection fraction (%) 60.8 ± 8.7 62.5 ± 6.3 0.242
LA diameter (mm) 48.25 ± 7.17 47.38 ± 4.24 0.384
LA appendage flow (cm/s) 23.36 ± 8.05 25.27 ± 15.9 0.549
SEC in LA appendage (%) 19.6 10.7 0.517
AF history (months) 46.6 ± 47.8 61.6 ± 76 0.223
AF, atrial fibrillation; LA, left atrium; SEC, spontaneous echo contrast
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Patients at risk
paroxysmal 62 59 49 35 22 15
persistent 52 46 35 21 17 13
HR (p value)
CI 95%
1.87 (0.332)
0.528-6.639
2.648 (0.076)
0.905-7.750
2.52 (0.049)
1.003-6.324
Fig. 2 Kaplan-Meier survival
curve of AF recurrence after
multiple procedures and hazard
ratios for arrhythmia recurrence at
6, 12months, and at the end of the
follow-up
Patients at risk
paroxysmal 62 51 44 32 21 14
persistent 57 49 38 24 15 11
HR (p value)
CI 95%
1.312 (0.592)
0.486-3.539
1.145 (0.718)
0.549-2.386
1.58 (0.105)
0.908-2.778
Fig. 1 Kaplan-Meier survival
curve of AF recurrence after a
single procedure and hazard ratios
for arrhythmia recurrence at 6,
12 months, and at the end of the
follow-up
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when pretreatment by antiarrhythmic drugs (AADs) resulted
in restoration of SR [6, 7]. Amiodarone has superior efficacy
in AF and reverses electrical, as well as structural remodeling
in an animal model [9], an effect not seen with class I and III
AADs [8]. Based on these data, we selected persAF patients
for PVI by the ability of amiodarone to result in a Bstep back^
to the paroxysmal stage and compared the outcome of PVI
with a matched cohort of paroxAF. In this population of last-
ing persAF, most patients Bstepped back^ on amiodarone.
They have undergone a mean of 1.46 procedures to perma-
nently isolate the PVs. No other ablation lesions were deliv-
ered, except for a CTI line in case of typical atrial flutter
documented before or during the procedure. Compared with
a matched paroxAF population undergoing the same proce-
dure, the persAF patients had comparable short-term freedom
from AF, but more late recurrences. This underlines that atrial
remodeling in persAF may be partly irreversible and patients
with a history of persAF, even if temporarily Bstepped back^
by AADs, are in a higher risk category for late recurrences
after PVI.
4.1 Comparison with previous studies
Two previous studies had indicated improved efficacy of
PVI in persAF when pretreatment with AADs results in
predominant SR. The first was a retrospective study of
patients treated with the class III AAD bepridil before
PVI [6]. Those who converted to SR on bepridil had
higher AF-free rate (87%) without AADs after PVI,
compared with those who did not (29%). In the second
study, bepridil or amiodarone was combined with class I
AADs ( f l eca in ide , ap r ind ine , p i l s i ca in ide , o r
propafenone) before PVI [7]. Similarly, restoration of
SR by AAD treatment predicted a more favorable
outcome (61% vs. 22%). These results have raised hope
that pretreatment of persAF patients by AADs to restore
SR may achieve a similarly high success rate for PVI as
in the case of paroxAF.
Khan et al. converted 71 persAF patients to SR and started
on dofetilide 3months prior to ablation [12]. Only two of them
returned to persAF; they did not respond to PVI. The success
rate in the remaining was not statistically different from the
control group of paroxAF patients at 12 months post-PVI
(70% vs. 75%). Our results contrast with those of Khan
et al., in that paroxAF patients had a more favorable long-
term outcome after PVI compared with persAF, even when
AAD pretreatment resulted in predominant SR. In our series,
paroxAF patients had considerably higher success at 6- and
12-months post procedure compared with those in Khan’s
study if we take into account our multiple-procedure success
rate. Since only PVI was done during the first and all subse-
quent procedures, a redo PVI was considered to be part of the
overall ablation effort and not a failure in our multiple-
procedure analysis. A more than double redo rate in our study,
compared with Khan’s, also reflects our commitment to
achieve permanent PVI in all patients. These differences along
with improvements in technology may explain the higher suc-
cess rate that is more in line with contemporary series of
paroxAF [13–15]. Further explanation for the contrasting re-
sults may lie in our patients having more dilated LA and
longer follow-up, which may enhance the difference between
groups. We followed our patients beyond 12 months because
the remarkably long half-life of amiodarone could obscure the
difference in a shorter timeframe.
Interestingly, none of abovementioned studies have utilized
amiodarone for reversing atrial remodeling before PVI in
persAF, despite its proven anti-remodeling action in animal
studies [8, 9].
Table 2 Clinical and
echocardiographic predictors of
AF recurrence
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Male gender 2.68 (0.996–7.210) 0.051 1.99 (0.707–5.645) 0.191
Age (years) 1.09 (1.018–1.168) 0.013 1.075 (1.002–1.154) 0.043
Hypertension 0.59 (0.121–2.755) 0.578
Diabetes mellitus 4.56 (0.572–36.342) 0.152
Coronary disease 1.31 (0.149–11.527) 0.808
AF type (persistent) 2.57 (0.939–7.038) 0.066 2.25 (0.790–6.405) 0.129
LA diameter 1.01 (0.969–1.108) 0.300
Ejection fraction 1.026 (0.958–1.098) 0.467
LA appendage flow 0.968 (0.905–1.035) 0.344
SEC in LA appendage 2.4 (0.604–9.541) 0.214
AF history 1.00 (0.993–1.008) 0.941
Redo procedure 1.72 (0.643–4.589) 0.281
AF, atrial fibrillation; LA, left atrium; SEC, spontaneous echo contrast
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4.2 The success of PVI alone in persAF
There is an ongoing debate on the role of additional ablation
beyond PVI. Despite incremental benefit shown in
nonrandomized studies implementing l inear and
electrogram-based ablation, recent randomized trials sug-
gested no role for these approaches [5, 16–18]. Therefore,
PVI remains the only proven strategy both for paroxAF and
persAF. However, up to half of the unselected patients expe-
rience a recurrence of persAF after PVI, compared with the
80–90% success rate in paroxAF [1, 13–15]. Recent random-
ized trials, using modern technology for PVI in persAF, report
success rates beyond 1 year, after multiple procedures, with-
out AADs to be 40–60% [5, 18–21]. Our result in persAF
patients selected by achieving Bone step back^ to a paroxys-
mal stage on amiodarone compares favorably with these and
approaches the 12-month success of PVI in paroxAF.
4.3 Limitations
The main limitation of this study is that persAF patients not
responding to amiodarone did not undergo ablation; therefore,
one cannot be sure that a Bstep back^ on amiodarone guaran-
tees a higher success rate of PVI, compared with those who
cannot be Bstepped back.^ However, this concept is clearly
supported by the abovementioned studies of AAD pretreat-
ment before PVI. In these, the success rate was between 0
[12] and 22–29% [6, 7] in patients who returned to persAF
despite AAD treatment. Moreover, performing PVI in SR has
been shown to result in a more favorable outcome, as opposed
to in persAF [21]. We felt it unethical to offer the procedure to
those who did not Bstep back^ considering such an unfavor-
able outcome. On the other hand, the success rates reported in
the above studies among patients who Bstepped back^ on
AAD (61–87%) and in our study are higher than in most
reports of an unselected persAF population undergoing PVI-
only and approaches the success seen in paroxAF. The definite
answer would however require a prospective, randomized
comparison.
Our study is also limited by the fact that efforts to better
characterize the atrial substrate and the changes it may show
during the study were not done, and echocardiograms were
only routinely available before initiation of amiodarone ther-
apy in persAF patients. Therefore, the change in LA volume
during sustained SR that might reflect reverse remodeling
could not be documented. Further limitation may be that
persAF patients were on amiodarone throughout the proce-
dure, while paroxAF patients were without AAD therapy.
However, both groups underwent the same, anatomically de-
termined PVI, without any effort to induce AF triggers.
Therefore, the presence of AAD during the procedure would
not be expected to have any influence on the long-term effi-
cacy of PVI. Another limitation may be that since continuous
rhythm monitoring by an implantable monitor after the proce-
dure was not performed, recurrent, asymptomatic episodes of
paroxAF may be less likely to be detected than persAF, pos-
sibly leading to a higher perceived success in the control
group. However, prolonged ECG monitoring for 7 days was
the standard for patients without symptoms to uncover asymp-
tomatic recurrences.
5 Conclusions
Selecting persAF patients for PVI based on the favorable re-
sponse to pretreatment with amiodarone—resulting in a Bstep
back^ to the paroxysmal stage—results in a long-term success
rate above 70%, which is higher than reported in most previ-
ous studies of PVI-only, offering a good strategy to improve
ablation success in persAF. This strategy might have an even
greater benefit in patients with more advanced disease than
those in our study (e.g., long-standing persAF), whose Bstep
back^ rate is likely lower. However, late recurrences are more
common in Bstepped back,^ compared with true paroxAF
patients, underlining the more advanced nature of their dis-
ease. This is important when consulting patients with a history
of persAF, even if predominantly in SR on AADs, about the
expected efficacy of PVI. Furthermore, after the procedure,
more vigilance is required in following these patients.
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